Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets (Q34017604)

30 July 2017

1 reference

title

Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets (English)

1 reference

30 July 2017

1 reference

Gustav Paumgartner

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

World Journal of Gastroenterology

30 July 2017

published in

1 reference

30 July 2017

volume

12

1 reference

30 July 2017

issue

28

1 reference

30 July 2017

page(s)

4445-4451

1 reference

Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Bile salt-induced apoptosis involves NADPH oxidase isoform activation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Enterohepatic bile salt transporters in normal physiology and liver disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Bile salt transporters: molecular characterization, function, and regulation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

The human bile salt export pump: characterization of substrate specificity and identification of inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Death receptor-mediated apoptosis and the liver

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Organ-specific alterations in RAR alpha:RXR alpha abundance regulate rat Mrp2 (Abcc2) expression in obstructive cholestasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Characterization of the mouse bile salt export pump overexpressed in the baculovirus system

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

5 July 2018

Hepatobiliary transport

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Inflammation-induced cholestasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Mechanisms and regulation of bile secretion

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Molecular pathogenesis of cholestasis.

5 July 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Consequences of bile duct obstruction on intestinal expression and function of multidrug resistance-associated protein 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized double-blind study controlled with placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.3748/WJG.V12.I28.4445

Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125628

Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy

29 October 2018

1 reference

12 December 2020

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

12 December 2020

Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment

1 reference

12 December 2020

Down-regulation of expression and function of the rat liver Na /bile acid cotransporter in extrahepatic cholestasis

1 reference

12 December 2020

Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis

1 reference

12 December 2020

Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis

1 reference

12 December 2020

Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes

1 reference

12 December 2020

Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver

1 reference

12 December 2020

Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat

1 reference

12 December 2020

Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study

1 reference

12 December 2020

Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up

1 reference

12 December 2020

Ursodeoxycholic Acid Delays the Onset of Esophageal Varices in Primary Biliary Cirrhosis

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V12.I28.4445

1 reference

30 July 2017

1 reference

30 July 2017

1 reference